Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm , MD, and Sean Pokorney , MD Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C. , Nov. 7, 2023 /PRNewswire/ — Milestone Pharmaceuticals Inc.
Related Posts
-
Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
-
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
